Why the study?
Does a booster dose of a multidose Sabin strain-based inactivated polio vaccine provide immune persistence, immunogenicity, and safety in infants aged 18 months?
Does a booster dose of a multidose Sabin strain-based inactivated polio vaccine provide immune persistence, immunogenicity, and safety in infants aged 18 months?
A booster dose of a multidose Sabin strain-based inactivated polio vaccine demonstrates robust immunogenicity and acceptable safety in 18-month-old infants.
May inform future polio booster strategies; hypothesis-generating for sIPV durability and routine use pending larger trials.
The 5-dose sIPV has shown promising immune persistence and robust immune response following a booster immunization, coupled with an acceptable safety profile.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: